For the year ending 2025-12-31, MIRM had $75,237K increase in cash & cash equivalents over the period. $54,873K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -23,363 |
| Stock-based compensation | 71,424 |
| Depreciation and amortization | 24,244 |
| Inventory reserves and firm commitment losses | -2,889 |
| Amortization of debt discount and offering costs | 1,739 |
| Loss from termination of revenue interest purchase agreement | 0 |
| Non-cash interest expense related to the revenue interest liability | 0 |
| Unrealized foreign exchange (gain) loss | 1,720 |
| Non-cash lease expense | 1,730 |
| Other | 1,401 |
| Accounts receivable | 48,055 |
| Prepaid and other current assets | 5,756 |
| Inventory | 8,448 |
| Other assets | 5,663 |
| Accounts payable, accrued expenses and other liabilities | 50,103 |
| Operating lease liabilities | -1,896 |
| Net cash provided by (used in) operating activities | 55,827 |
| Purchase of investments | 97,425 |
| Proceeds from maturities of investments | 74,425 |
| Purchase of property and equipment | 954 |
| Cash paid for acquisition | 0 |
| Payments made for additions to intangible assets | 0 |
| Net cash used in investing activities | -23,954 |
| Proceeds from issuance of common stock in private placement, net of issuance costs | 0 |
| Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs | 0 |
| Proceeds from issuance of convertible notes, net | 0 |
| Proceeds from issuance of common stock pursuant to equity plans | 40,142 |
| Payments of deferred offering costs | 0 |
| Payments on revenue interest liability | 0 |
| Net cash provided by financing activities | 40,142 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 3,222 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 75,237 |
| Cash, cash equivalents and restricted cash at beginning of period | 222,928 |
| Cash, cash equivalents and restricted cash at end of period | 298,165 |
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)